"they couldn't even imagine a label that would step into those AMRN patents."? Not true as Generic defendants certainly knew REDUCE-IT was ongoing and has the potential to gain subsequent label expansion.
Older...The FDA CRL'd Anchor because it was not "obvious" to them that Vascepa would work...Amarin continued the R-IT study...at the risk of bankrupting the company, to show that chronic treatment with Vascepa over a FIVE YEAR period does, in fact, work!
Market Data 
Markets 
AI
